Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Opinion: To advance sustainable stewardship, we must document not only biodiversity but geodiversity.

Schrodt F, Bailey JJ, Kissling WD, Rijsdijk KF, Seijmonsbergen AC, van Ree D, Hjort J, Lawley RS, Williams CN, Anderson MG, Beier P, van Beukering P, Boyd DS, Brilha J, Carcavilla L, Dahlin KM, Gill JC, Gordon JE, Gray M, Grundy M, Hunter ML, Lawler JJ, Monge-Ganuzas M, Royse KR, Stewart I, Record S, Turner W, Zarnetske PL, Field R.

Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16155-16158. doi: 10.1073/pnas.1911799116. No abstract available.

2.

Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B.

Gill JC, Roberts J, Li Y, Castaman G.

Haemophilia. 2019 May;25(3):e219-e222. doi: 10.1111/hae.13735. Epub 2019 Mar 13. No abstract available.

PMID:
30866086
3.

Risk factors associated with invasive orthopaedic interventions in males with haemophilia enrolled in the Universal Data Collection program from 2000 to 2010.

Tobase P, Lane H, Siddiqi AE, Soucie JM, Ingram-Rich R, Ward S, Gill JC; Hemophilia Treatment Center Network (HTCN) Study Investigators.

Haemophilia. 2018 Nov;24(6):964-970. doi: 10.1111/hae.13511. Epub 2018 Jun 29.

PMID:
29957840
4.

A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA.

Blood Adv. 2018 Jun 12;2(11):1325-1333. doi: 10.1182/bloodadvances.2018018226.

5.

Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project.

Manco-Johnson MJ, Soucie JM, Gill JC; Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network.

Blood. 2017 Apr 27;129(17):2368-2374. doi: 10.1182/blood-2016-02-683169. Epub 2017 Feb 9.

6.

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Kulkarni R, Presley RJ, Lusher JM, Shapiro AD, Gill JC, Manco-Johnson M, Koerper MA, Abshire TC, DiMichele D, Hoots WK, Mathew P, Nugent DJ, Geraghty S, Evatt BL, Soucie JM.

Haemophilia. 2017 Mar;23(2):207-214. doi: 10.1111/hae.13081. Epub 2016 Nov 4.

7.

Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models.

Marek E, Momper JD, Hines RN, Takao CM, Gill JC, Pravica V, Gaedigk A, Burckart GJ, Neville KA.

J Pediatr Pharmacol Ther. 2016 May-Jun;21(3):224-32. doi: 10.5863/1551-6776-21.3.224.

8.

Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.

Klamroth R, Simpson M, von Depka-Prondzinski M, Gill JC, Morfini M, Powell JS, Santagostino E, Davis J, Huth-Kühne A, Leissinger C, Neumeister P, Bensen-Kennedy D, Feussner A, Limsakun T, Zhou M, Veldman A, St Ledger K, Blackman N, Pabinger I.

Haemophilia. 2016 Sep;22(5):730-8. doi: 10.1111/hae.12985. Epub 2016 Jul 19.

PMID:
27434619
9.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellmann A, Santagostino E, Baker RI, Fischer K, Gill JC, P'Ng S, Chowdary P, Escobar MA, Khayat CD, Rusen L, Bensen-Kennedy D, Blackman N, Limsakun T, Veldman A, St Ledger K, Pabinger I; AFFINITY Investigators.

Blood. 2016 Aug 4;128(5):630-7. doi: 10.1182/blood-2016-01-687434. Epub 2016 Jun 21.

10.

Rapid discrimination of the phenotypic variants of von Willebrand disease.

Roberts JC, Morateck PA, Christopherson PA, Yan K, Hoffmann RG, Gill JC, Montgomery RR; Zimmerman Program Investigators.

Blood. 2016 May 19;127(20):2472-80. doi: 10.1182/blood-2015-11-664680. Epub 2016 Feb 25.

11.

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lillicrap D, Peake IR, Montgomery RR.

Blood. 2016 May 19;127(20):2481-8. doi: 10.1182/blood-2015-10-673681. Epub 2016 Feb 9.

12.

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.

Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW, Obermann-Slupetzky O, Chapman M, Fritsch S, Pavlova BG, Presch I, Ewenstein B.

Blood. 2015 Oct 22;126(17):2038-46. doi: 10.1182/blood-2015-02-629873. Epub 2015 Aug 3. Erratum in: Blood. 2016 Jun 2;127(22):2777.

13.

Substance p regulates puberty onset and fertility in the female mouse.

Simavli S, Thompson IR, Maguire CA, Gill JC, Carroll RS, Wolfe A, Kaiser UB, Navarro VM.

Endocrinology. 2015 Jun;156(6):2313-22. doi: 10.1210/en.2014-2012. Epub 2015 Apr 9.

14.

Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.

Holm E, Abshire TC, Bowen J, Álvarez MT, Bolton-Maggs P, Carcao M, Federici AB, Gill JC, Halimeh S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E.

Blood Coagul Fibrinolysis. 2015 Jun;26(4):383-8. doi: 10.1097/MBC.0000000000000257.

PMID:
25688461
15.

Crucial role for the VWF A1 domain in binding to type IV collagen.

Flood VH, Schlauderaff AC, Haberichter SL, Slobodianuk TL, Jacobi PM, Bellissimo DB, Christopherson PA, Friedman KD, Gill JC, Hoffmann RG, Montgomery RR; Zimmerman Program Investigators.

Blood. 2015 Apr 2;125(14):2297-304. doi: 10.1182/blood-2014-11-610824. Epub 2015 Feb 6.

16.

Thrombolysis in pediatric stroke study.

Rivkin MJ, deVeber G, Ichord RN, Kirton A, Chan AK, Hovinga CA, Gill JC, Szabo A, Hill MD, Scholz K, Amlie-Lefond C.

Stroke. 2015 Mar;46(3):880-5. doi: 10.1161/STROKEAHA.114.008210. Epub 2015 Jan 22. No abstract available.

17.

Thromboembolic incidence with transiently elevated levels of coagulation factors in patients with von Willebrand disease treated with VWF:FVIII concentrate during surgery.

Gill JC, Mannucci PM.

Haemophilia. 2014 Nov;20(6):e404-6. doi: 10.1111/hae.12498. Epub 2014 Aug 12. No abstract available.

PMID:
25113065
18.

Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.

Leissinger C, Josephson CD, Granger S, Konkle BA, Kruse-Jarres R, Ragni MV, Journeycake JM, Valentino L, Key NS, Gill JC, McCrae KR, Neufeld EJ, Manno C, Raffini L, Saxena K, Torres M, Marder V, Bennett CM, Assmann SF.

Thromb Haemost. 2014 Sep 2;112(3):445-58. doi: 10.1160/TH14-01-0078. Epub 2014 Jun 12.

19.

Emergence of the primary pediatric stroke center: impact of the thrombolysis in pediatric stroke trial.

Bernard TJ, Rivkin MJ, Scholz K, deVeber G, Kirton A, Gill JC, Chan AK, Hovinga CA, Ichord RN, Grotta JC, Jordan LC, Benedict S, Friedman NR, Dowling MM, Elbers J, Torres M, Sultan S, Cummings DD, Grabowski EF, McMillan HJ, Beslow LA, Amlie-Lefond C; Thrombolysis in Pediatric Stroke Study.

Stroke. 2014 Jul;45(7):2018-23. doi: 10.1161/STROKEAHA.114.004919. Epub 2014 Jun 10.

20.

Diagnosis of von Willebrand disease in people with type O blood.

Gill JC.

Clin Adv Hematol Oncol. 2014 Feb;12(2):119-21. No abstract available.

PMID:
24892257
21.

Approach to acute ischemic stroke in childhood.

Amlie-Lefond C, Gill JC.

Curr Treat Options Cardiovasc Med. 2014 Jan;16(1):276. doi: 10.1007/s11936-013-0276-z.

PMID:
24390791
22.

Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders.

Leissinger C, Carcao M, Gill JC, Journeycake J, Singleton T, Valentino L.

Haemophilia. 2014 Mar;20(2):158-67. doi: 10.1111/hae.12254. Epub 2013 Aug 12. Review.

PMID:
23937614
23.

Thromboelastography in the assessment of bleeding following surgery for congenital heart disease.

Niebler RA, Gill JC, Brabant CP, Mitchell ME, Nugent M, Simpson P, Tweddell JS, Ghanayem NS.

World J Pediatr Congenit Heart Surg. 2012 Oct 1;3(4):433-8. doi: 10.1177/2150135112447540.

PMID:
23804904
24.

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM; rVWF Ad Hoc Study Group.

Blood. 2013 Aug 1;122(5):648-57. doi: 10.1182/blood-2013-01-479527. Epub 2013 Jun 18.

25.

Central precocious puberty caused by mutations in the imprinted gene MKRN3.

Abreu AP, Dauber A, Macedo DB, Noel SD, Brito VN, Gill JC, Cukier P, Thompson IR, Navarro VM, Gagliardi PC, Rodrigues T, Kochi C, Longui CA, Beckers D, de Zegher F, Montenegro LR, Mendonca BB, Carroll RS, Hirschhorn JN, Latronico AC, Kaiser UB.

N Engl J Med. 2013 Jun 27;368(26):2467-75. doi: 10.1056/NEJMoa1302160. Epub 2013 Jun 5.

26.

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR.

Blood. 2013 May 2;121(18):3742-4. doi: 10.1182/blood-2012-12-471672. Epub 2013 Mar 21.

27.

Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.

Larsen DM, Haberichter SL, Gill JC, Shapiro AD, Flood VH.

Haemophilia. 2013 Jul;19(4):590-4. doi: 10.1111/hae.12117. Epub 2013 Mar 18.

28.

The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia.

Gupta S, Siddiqi AE, Soucie JM, Manco-Johnson M, Kulkarni R, Lane H, Ingram-Rich R, Gill JC; Joint Outcomes Committee of Universal Data Collection and the Hemophilia Treatment Centres Network.

Br J Haematol. 2013 May;161(3):424-33. doi: 10.1111/bjh.12267. Epub 2013 Feb 22.

29.

Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.

Valentino LA, Allen G, Gill JC, Hurlet A, Konkle BA, Leissinger CA, Luchtman-Jones L, Powell J, Reding M, Stine K.

Haemophilia. 2013 May;19(3):e151-66. doi: 10.1111/hae.12095. Epub 2013 Feb 4.

PMID:
23374141
30.

Collagen binding provides a sensitive screen for variant von Willebrand disease.

Flood VH, Gill JC, Friedman KD, Christopherson PA, Jacobi PM, Hoffmann RG, Montgomery RR, Haberichter SL; Zimmerman Program Investigators.

Clin Chem. 2013 Apr;59(4):684-91. doi: 10.1373/clinchem.2012.199000. Epub 2013 Jan 22.

31.

Increased neurokinin B (Tac2) expression in the mouse arcuate nucleus is an early marker of pubertal onset with differential sensitivity to sex steroid-negative feedback than Kiss1.

Gill JC, Navarro VM, Kwong C, Noel SD, Martin C, Xu S, Clifton DK, Carroll RS, Steiner RA, Kaiser UB.

Endocrinology. 2012 Oct;153(10):4883-93. Epub 2012 Aug 14.

32.

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.

Kempton CL, Abshire TC, Deveras RA, Hoots WK, Gill JC, Kessler CM, Key NS, Konkle BA, Kuriakose P, Macfarlane DE, Bergman G.

Haemophilia. 2012 Sep;18(5):798-804. doi: 10.1111/j.1365-2516.2012.02789.x. Epub 2012 Apr 19.

PMID:
22512291
33.

Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.

Flood VH, Gill JC, Christopherson PA, Wren JS, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR.

J Thromb Haemost. 2012 Jul;10(7):1425-32. doi: 10.1111/j.1538-7836.2012.04747.x.

34.

Critical von Willebrand factor A1 domain residues influence type VI collagen binding.

Flood VH, Gill JC, Christopherson PA, Bellissimo DB, Friedman KD, Haberichter SL, Lentz SR, Montgomery RR.

J Thromb Haemost. 2012 Jul;10(7):1417-24. doi: 10.1111/j.1538-7836.2012.04746.x.

35.

Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.

Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL.

Blood. 2012 May 10;119(19):4543-53. doi: 10.1182/blood-2011-06-360875. Epub 2012 Mar 19.

36.

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.

Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR.

Blood. 2012 Mar 1;119(9):2135-40. doi: 10.1182/blood-2011-10-384610. Epub 2011 Dec 23.

37.

Von Willebrand disease in the United States: a perspective from Wisconsin.

Flood VH, Gill JC, Friedman KD, Bellissimo DB, Haberichter SL, Montgomery RR.

Semin Thromb Hemost. 2011 Jul;37(5):528-34. doi: 10.1055/s-0031-1281039. Epub 2011 Nov 18. Review.

38.

Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres.

Byams VR, Kouides PA, Kulkarni R, Baker JR, Brown DL, Gill JC, Grant AM, James AH, Konkle BA, Maahs J, Dumas MM, McAlister S, Nance D, Nugent D, Philipp CS, Soucie JM, Stang E; Haemophilia Treatment Centres Network Investigators.

Haemophilia. 2011 Jul;17 Suppl 1:6-13. doi: 10.1111/j.1365-2516.2011.02558.x.

39.

The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.

Kessler CM, Friedman K, Schwartz BA, Gill JC, Powell JS; Wilate PK Study Investigators.

Thromb Haemost. 2011 Aug;106(2):279-88. doi: 10.1160/TH11-02-0057. Epub 2011 Jul 4.

PMID:
21725579
40.

von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.

Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, Manco-Johnson M.

Haemophilia. 2011 Nov;17(6):895-905. doi: 10.1111/j.1365-2516.2011.02534.x. Epub 2011 Apr 27.

PMID:
21535320
41.

Naturally occurring CD4+ T-cell epitope variants act as altered peptide ligands leading to impaired helper T-cell responses in hepatitis C virus infection.

Cusick MF, Yang M, Gill JC, Eckels DD.

Hum Immunol. 2011 May;72(5):379-85. doi: 10.1016/j.humimm.2011.02.010. Epub 2011 Mar 4.

42.

Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).

Neufeld EJ, Kessler CM, Gill JC, Wilke CT, Cooper DL; Htrs Investigators.

Haemophilia. 2011 Jul;17(4):650-6. doi: 10.1111/j.1365-2516.2010.02483.x. Epub 2011 Feb 7.

PMID:
21299750
43.

Hepatitis C virus induces regulatory T cells by naturally occurring viral variants to suppress T cell responses.

Cusick MF, Schiller JJ, Gill JC, Eckels DD.

Clin Dev Immunol. 2011;2011:806061. doi: 10.1155/2011/806061. Epub 2010 Dec 6.

44.

Pharmacology in childhood arterial ischemic stroke.

Amlie-Lefond C, Gill JC.

Semin Pediatr Neurol. 2010 Dec;17(4):237-44. doi: 10.1016/j.spen.2010.10.006. Review.

PMID:
21183130
45.

Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.

Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR.

Blood. 2011 Feb 10;117(6):e67-74. doi: 10.1182/blood-2010-08-299016. Epub 2010 Dec 10.

46.

Reproductive hormone-dependent and -independent contributions to developmental changes in kisspeptin in GnRH-deficient hypogonadal mice.

Gill JC, Wang O, Kakar S, Martinelli E, Carroll RS, Kaiser UB.

PLoS One. 2010 Jul 30;5(7):e11911. doi: 10.1371/journal.pone.0011911.

47.

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR.

Blood. 2010 Jul 15;116(2):280-6. doi: 10.1182/blood-2009-10-249102. Epub 2010 Mar 15.

48.

Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.

Flood VH, Friedman KD, Gill JC, Morateck PA, Wren JS, Scott JP, Montgomery RR.

J Thromb Haemost. 2009 Nov;7(11):1832-9. doi: 10.1111/j.1538-7836.2009.03594.x. Epub 2009 Aug 19.

49.

Expression of a gonadotropin-releasing hormone receptor-simian virus 40 T-antigen transgene has sex-specific effects on the reproductive axis.

Jeong KH, Gill JC, Nosé V, Parlow AF, Carroll RS, Kaiser UB.

Endocrinology. 2009 Jul;150(7):3383-91. doi: 10.1210/en.2008-1362. Epub 2009 Mar 12.

50.

Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.

Gao C, Boylan B, Bougie D, Gill JC, Birenbaum J, Newman DK, Aster RH, Newman PJ.

J Clin Invest. 2009 Mar;119(3):504-11. doi: 10.1172/JCI36745. Epub 2009 Feb 9.

Supplemental Content

Support Center